Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

NCT03052517 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2538

Enrollment

INDUSTRY

Sponsor class

Stopped Company Decision

Conditions

Asthma

Interventions

DRUG: QAW039 150 mg
DRUG: QAW039 450 mg
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals